Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of
Vandetanib (CAPRELSA) in Healthy Subjects when a Single Oral Dose of Vandetanib 300 mg is
Administered Alone and in Combination with Omeprazole or Ranitidine

Inclusion Criteria:

- Provision of signed and dated, written informed consent prior to any study-specific
procedures

- Volunteers must be males or females aged 18 to 50 years and with a weight of at least
50 kg and body mass index (BMI) between 18 and 30 kg/m2

- Inclusive Females must have a negative pregnancy test at screening and on admission
to the study center

- Females must not be lactating and must be of non childbearing potential defined as
postmenopausal or documentation of irreversible surgical sterilization.

Exclusion Criteria:

- History of any clinically significant disease or disorder such as gastrointestinal,
hepatic, renal or skin disease.

- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity

- Volunteers who smoke more than 5 cigarettes per day or are unable to refrain from
smoking while resident in the study center

- Screening blood pressure of greater than 140/90 mmHg and/or a resting heart rate of
less than 45 beats per minute (repeat test allowed at the Investigator's discretion

- Clinically significant abnormal12-lead ECG as assessed by the Investigator

- QTcF interval greater than 450 ms Any positive result on screening for serum
hepatitis B surface antigen, hepatitis C antibody

- Human immunodeficiency virus (HIV), or positive screen for drugs of abuse.